Filed Pursuant to Rule 424(b)(5)
Registration No. 333-264193
PROSPECTUS SUPPLEMENT
(To the Prospectus dated April 19, 2022)
9,090,910 Shares of Common Stock
MODULAR MEDICAL, INC.
We are offering 9,090,910 shares
of our common stock.
Our common stock is listed
for trading on the Nasdaq Capital Market under the symbol “MODD.” On February 15, 2024, the last reported sale price of our
common stock was $1.255 per share
As
of February 15, 2024, the aggregate market value worldwide of our outstanding voting and non-voting common equity held by non-affiliates,
as calculated pursuant to the rules of the Securities and Exchange Commission, was approximately $35,220,929, based on 16,230,843 common
shares outstanding held by non-affiliates at a per common share price of $2.17 based on the closing sale price of our common shares on
The Nasdaq Capital Market on January 2, 2024. During the prior 12 calendar month period that ends on and includes the date hereof,
we have offered and sold 153,879 shares of our common stock pursuant to General Instruction I.B.6 to Form S-3 having
an aggregate offering price of approximately $286,120 under our sales agreement.
This offering is being underwritten
on a firm commitment basis. We have granted the underwriters an option to buy up to an additional 1,321,989 shares of common stock
from us to cover over-allotments. The underwriters may exercise this option at any time and from time to time during the 30-day period
from the date of this prospectus supplement.
| | |
No Exercise of
Over-Allotment | | |
Full Exercise of
Over-Allotment | |
| | |
Per Share | | |
Total | | |
Per Share | | |
Total | |
| Public offering price | |
$ | 1.100 | | |
$ | 10,000,001 | | |
$ | 1.10 | | |
$ | 11,454,189 | |
| Underwriting discounts and commissions(1)(2) | |
$ | 0.077 | | |
$ | 700,000 | | |
$ | 0.077 | | |
$ | 801,793 | |
| Proceeds to us, before expenses | |
$ | 1.023 | | |
$ | 9,300,001 | | |
$ | 1.023 | | |
$ | 10,652,395 | |
| (1) |
We have agreed to reimburse the underwriter for certain expenses. See “Underwriting” on page S-11 of this prospectus supplement for additional disclosures regarding underwriting discounts, commissions and estimated offering expenses |
Our business and an investment
in our common stock involve significant risks. These risks are described under the caption “Risk Factors” beginning on page
S-3 of this prospectus supplement. You should also consider the risk factors described in the documents incorporated by reference into
this prospectus supplement and the accompanying prospectus, including the risk factors described in our Annual Report on Form 10-K for
the fiscal year ended March 31, 2023.
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy
or accuracy of this prospectus supplement. Any representation to the contrary is a criminal offense.
The underwriters expect to
deliver the shares against payment of common stock on February 21, 2024.
The date of this prospectus supplement is February
15, 2024
Sole Bookrunner
Titan Partners Group
a division of American Capital Partners
TABLE OF CONTENTS
PROSPECTUS SUPPLEMENT
PROSPECTUS DATED APRIL 19, 2022
ABOUT
THIS PROSPECTUS SUPPLEMENT
This document is in two parts.
The first part is the prospectus supplement, which describes the specific terms of this offering. The second part is the accompanying
prospectus, which provides more general information, some of which may not apply to this offering. Before investing in our securities,
we urge you to carefully read this prospectus supplement and the accompanying prospectus, as well as the documents incorporated by reference
herein and therein. This prospectus supplement may add to, update or change information contained in the accompanying prospectus or the
documents incorporated by reference herein or therein. If information included in this prospectus supplement is inconsistent with the
accompanying prospectus or the information incorporated by reference herein or therein, then this prospectus supplement will be deemed
to modify or supersede the information in the accompanying prospectus and such documents incorporated by reference.
This prospectus supplement
and the accompanying prospectus dated April 19, 2022 are part of a registration statement (Registration No. 333-264193) on Form S-3 that
we filed with the Securities and Exchange Commission, or SEC, using a “shelf” registration process under which we may from
time to time offer and sell any combination of the securities described in that accompanying prospectus up to a total dollar amount of
$50 million. This prospectus supplement relates to the offering of shares of our common stock by us.
This prospectus supplement,
the accompanying prospectus and any free writing prospectus prepared by us or on our behalf contain and incorporate by reference information
that you should consider when making your investment decision. We have not, and the underwriters have not, authorized any other person
to provide you with different or additional information. We and the underwriters take no responsibility for, and can provide no assurance
as to, the reliability of any other information that any other person may give you. We are not, and the underwriters are not, making an
offer to sell or soliciting an offer to buy these securities under any circumstance in any jurisdiction where the offer or solicitation
is not permitted. You should assume that the information contained in this prospectus supplement, the accompanying prospectus and any
free writing prospectus prepared by us or on our behalf is accurate only as of the date of the respective document in which the information
appears, and that any information in documents that we have incorporated by reference is accurate only as of the date of the document
incorporated by reference, regardless of the time of delivery of this prospectus supplement or any sale of a security. Our business, financial
condition, results of operations and prospects may have changed since those dates.
References in this prospectus
supplement to “Modular Medical,” “the Company,” “we,” “our,” and “us” refer
to Modular Medical, Inc., a Nevada corporation, and its subsidiary, Quasuras, Inc.
PROSPECTUS SUPPLEMENT SUMMARY
Overview
We are a development-stage
medical device company focused on the design, development and commercialization of an innovative insulin pump using modernized technology
to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, our MODD1 product, we seek
to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care that presently-available
insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and
day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated “super users” and
expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device
adoption, type 2 diabetes markets.
Recent Developments
On February 15, 2024, the
Company filed an amendment to its Third Amended and Restated Articles of Incorporation with the Secretary of State of Nevada to increase
the Company’s authorized shares of common stock from 50,000,000 to 100,000,000.
Implications of Being a Smaller Reporting Company
We are a “smaller reporting
company” as defined in the Exchange Act. We may take advantage of certain of the scaled disclosures available to smaller reporting
companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by
non-affiliates is less than $250 million measured on the last business day of our second fiscal quarter, or our annual revenue is less
than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is
less than $700 million measured on the last business day of our second fiscal quarter.
Corporate Information
We are a Nevada corporation,
and Quasuras, Inc., a Delaware corporation, is our only subsidiary. Our corporate headquarters and operating facilities are located at
10740 Thornmint Road, San Diego, CA 92127. Our telephone number is (858) 800-3500. We maintain a website at www.modular-medical.com. The
information contained on or that can be accessed through our website is not incorporated by reference into this prospectus supplement
and you should not consider information on our website to be part of this prospectus supplement or in deciding whether to purchase our
securities.
THE OFFERING
| Common stock offered by us |
|
9,090,910 shares |
| |
|
|
| |
|
|
| Common stock to be outstanding immediately after this offering |
|
30,989,968 shares (assuming no exercise of the over-allotment option |
| |
|
|
| Underwriters’ over-allotment option |
|
1,321,989 shares |
| |
|
|
| Use of proceeds |
|
We estimate that the net proceeds to us from this offering will be
approximately $8.95 million, or $10.3 million if the underwriters exercise their option to purchase additional shares in full, in
each case after deducting underwriting discounts and commissions and estimated expenses payable by us. We intend to use the net proceeds
from this offering for general corporate purposes, working capital purposes and capital expenditures. See “Use of Proceeds.” |
| |
|
|
| Risk factors |
|
Investing in our common stock involves a high degree of risk. You should carefully read “Risk Factors” on page S-3 of this prospectus supplement and page 2 of the accompanying prospectus as well as other information included and incorporated by reference in this prospectus supplement for a discussion of factors that you should consider before deciding to invest in our common stock. |
| |
|
|
| Nasdaq Capital Market symbol |
|
MODD. See “Description of the Securities We Are Offering” on page S-9 of this prospectus supplement. |
| |
|
|
| Insider Participation |
|
An affiliate of one of our directors and our chief executive officer has indicated interests in purchasing up to an aggregate of approximately 900,000 shares of our common stock in this offering at the public offering price per share and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer, or no shares in this offering to such potential investors, and such potential investors may determine to purchase more, fewer, or no shares in this offering. The underwriters will receive the same underwriting discount with respect to these shares of our common stock as they will from any other shares of our common stock to be sold to the public in this offering. |
| (1) |
The number of shares of common stock shown above to be outstanding immediately following this offering is based on 21,899,058 shares outstanding as of February 15, 2024 and excludes: |
| ● | 767,796
shares of our common stock issuable upon the exercise of warrants with an exercise price of $6.00 per share; |
| ● | 5,449,478
shares of our common stock issuable upon the exercise of warrants with an exercise price of $6.60 per share; |
| ● | 543,313
shares of our common stock issuable upon the exercise of warrants with an exercise price of $1.32 per share; |
| ● | 4,536,783
shares of our common stock issuable upon the exercise of warrants with an exercise price of $1.22 per share; |
| ● | 1,348,314
shares of our common stock issuable upon exercise of pre-funded warrants with an exercise price of $0.01 per share; |
| ● | 3,657,466
shares of our common stock issuable upon exercise of outstanding stock options with a weighted average exercise price of approximately
$3.72 per share; |
| ● | 208,332
shares of our common stock issuable upon vesting of restricted stock units; and |
| ● | 3,686,901
shares of our common stock reserved for issuance pursuant to future awards under our Amended and Restated 2017 Equity Incentive Plan,
or the 2017 Plan. |
Except as otherwise indicated,
all information in this prospectus supplement assumes (i) no exercise by the underwriters of their over-allotment option and (ii) no exercise
of the outstanding options and warrants described above.
RISK
FACTORS
You should carefully consider
these risk factors, the risk factors in the accompanying prospectus, the risks described in the documents incorporated by reference in
this prospectus supplement, and all of the other information herein and therein before making an investment decision. See the section
entitled “Risk Factors” in the accompanying prospectus and in our Annual Report on Form 10-K for the fiscal year ended March
31, 2023, which is incorporated herein by reference, for additional risk factors that affect us.
Risks Related to this Offering
Investors in this offering will experience
immediate substantial dilution in the net tangible book value per share of our common stock.
You will suffer immediate
and substantial dilution in the net tangible book value per share of common stock you purchase in this offering because the price per
share of our common stock being offered hereby is substantially higher than the book value per share of our common stock. Our net tangible
book value as of December 31, 2023 was approximately $0.18 per share of common stock. Based on an offering price of $1.10 per share in
this offering, if you purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of $0.66 per
share in the net tangible book value of the common stock.
We will likely issue additional common stock
in the future, which would dilute the holdings of our existing stockholders.
In the future, we will likely
issue additional shares of our common stock or securities convertible into or exchangeable or exercisable for our common stock, resulting
in the dilution of the ownership interests of our stockholders. We may issue additional shares of our common stock or securities convertible
into or exchangeable or exercisable for our common stock in connection with hiring or retaining personnel, future acquisitions or future
capital-raising transactions or other business purposes. Moreover, the exercise of our existing outstanding warrants and stock options,
which are exercisable for or convertible into shares of our common stock, would dilute our existing holders of common stock. On February
13, 2024, our stockholders approved increases in: i) the number of shares of common stock reserved for issuance under the 2017 Plan by
3,000,000 shares and ii) the authorized shares of our common stock to 100,000,000 from 50,000,000.
A large number of shares may be sold in the
market following this offering, which may depress the market price of our common stock.
Shares of our common stock
sold in the offering are freely tradable without restriction or further registration under the Securities Act. Moreover, from time to
time, certain of our stockholders may be eligible to sell all or some of their shares of common stock by means of ordinary brokerage transactions
in the open market or otherwise. As a result, a substantial number of shares of our common stock may be sold in the public market following
this offering, which may cause the market price of our common stock to decline. If there are more shares of common stock offered for sale
than buyers are willing to purchase, then the market price of our common stock may decline.
Management will have broad discretion as to
the use of the proceeds from this offering, and may not use the proceeds to effectively improve our business.
Our management will have broad
discretion as to the application of the net proceeds from this offering and could use them for purposes other than those contemplated
at the time of the offering. Our management may use the net proceeds for corporate purposes that may not improve our operating results,
financial condition or market value.
We might not be able to continue as a going
concern.
Our consolidated financial
statements as of March 31, 2023 have been prepared under the assumption that we will continue as a going concern for the next twelve months.
At December 31, 2023, we had cash and cash equivalents of $2.0 million and an accumulated deficit of $61.6 million. In May 2023, we completed
a public offering of common stock and warrants for net proceeds to us of approximately $9.7 million. As of the date of this prospectus,
we believe that, prior to this offering, we do not have sufficient resources available to fund our business operations and satisfy our
obligations beyond the quarter ending March 31, 2024. As a result of our expected operating losses and cash burn for the foreseeable future
and recurring losses from operations, if we are unable to raise sufficient capital through additional debt or equity arrangements, there
will be uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial
doubt as to our ability to continue as a going concern. If we cannot continue as a viable entity, our stockholders would likely lose most
or all of their investment in us.
If we are unable to generate
sustainable operating profit and sufficient cash flows, then our future success will depend on our ability to raise capital. We intend
to seek additional financing and evaluate financing alternatives in order to meet our cash requirements for the foreseeable future. We
cannot be certain that raising additional capital, whether through selling additional debt or equity securities or obtaining a line of
credit or other loan, will be available to us or, if available, will be on terms acceptable to us. If we issue additional securities to
raise funds, these securities may have rights, preferences, or privileges senior to those of our common stock, and our current stockholders
may experience dilution. If we are unable to obtain funds when needed or on acceptable terms, we may be required to curtail our current
product development programs, cut operating costs, forego future development and other opportunities or even terminate our operations.
We are a developmental stage medical device
company and have a history of significant operating losses; we expect to continue to incur operating losses, and we may never achieve
or maintain profitability.
As a development-stage enterprise,
we do not currently have sufficient revenues to generate cash flows to cover operating expenses. Since our inception, we have incurred
operating losses in each year due to costs incurred in connection with research and development activities and general and administrative
expenses associated with our operations. For the nine months ended December 31, 2023 and year ended March 31, 2023, we incurred net losses
of approximately $13.2 million and $13.9 million, respectively. As a result, we need to raise additional capital in the future, which
may or may not be available to us at all or only on unfavorable terms.
We expect to incur losses
for the foreseeable future as we continue the development of, and seek regulatory clearance and approvals for, our insulin pump. As our
MODD1 insulin pump is currently our only product, if it fails to gain regulatory approval and market acceptance, we will not be able to
generate any revenue, or explore other opportunities to enhance stockholder value, such as through a sale. If we fail to generate revenue
and eventually become profitable, or if we are unable to fund our continuing losses, our stockholders could lose all or a substantial
part of their investment.
We will need substantial additional funding
to complete subsequent phases of the development of our insulin pump product candidate and to operate our business and such funding may
not be available or, if it is available, such financing is likely to substantially dilute our existing stockholders.
The discovery, development,
and commercialization of new medical devices, such as our insulin pump, entails significant costs. While we believe that we have generally
completed the engineering and mechanical aspects of our insulin pump and cartridge along with production-level assembly equipment, we
still must refine and finalize our insulin pump to, among other things, meet the general needs and preferences of the Almost Pumper marketplace
and the guidelines of third-party payors. To enable us to accomplish these and other related items and continue to operate our business,
we will need to raise substantial additional capital and/or enter into strategic partnerships or joint ventures to enable us to:
| ● | fund
clinical studies and seek regulatory approvals; |
| ● | build
or access manufacturing and commercialization capabilities; |
| ● | develop,
test, and, if approved, market our product candidate; |
| ● | acquire
or license additional internal systems and other infrastructure; and |
| ● | hire
and support additional management, engineering and scientific personnel. |
Until we can generate a sufficient
amount of product revenue to finance our cash requirements, which we may never achieve, we expect to finance our cash needs primarily
through public or private equity offerings, debt financings or through the establishment of possible strategic alliances. We may in the
future seek additional capital from public or private offerings of our capital stock or borrow additional amounts under new credit lines
or from other sources. If we issue equity or debt securities to raise additional funds, our existing stockholders may experience dilution,
we may incur significant financing costs, and the new equity or debt securities may have rights, preferences and privileges senior to
those of our existing stockholders. In addition, if we raise additional funds through collaborations, licensing, joint ventures, strategic
alliances, partnership arrangements or other similar arrangements, it may be necessary to relinquish valuable rights to the MODD1 pump
or our potential future products or proprietary technologies or grant licenses on terms that are not favorable to us.
We cannot be certain that
additional funding will be available on acceptable terms, or at all. If we are not able to secure additional equity funding when needed,
we may have to delay, reduce the scope of, or eliminate one or more of our clinical studies, development programs or future commercialization
initiatives. In addition, any additional equity funding that we do obtain will dilute the ownership held by our existing equity holders.
The amount of this dilution may be substantially increased if the trading price of our common stock is lower at the time of any financing.
Regardless, the economic dilution to stockholders will be significant if our stock price does not increase significantly, or if the effective
price of any sale is below the price paid by a particular stockholder. Any debt financing that we obtain in the future could involve substantial
restrictions on activities and creditors could seek a pledge of some or all of our assets. We have not identified potential sources for
such financing that we will require, and we do not have commitments from any third parties to provide any future debt financing. If we
fail to obtain funding as needed, we may be forced to cease or scale back operations, and our business, prospects, results of operations,
financial condition and stock price would be adversely affected.
CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement,
the accompanying prospectus and the documents we incorporate by reference in this prospectus supplement and the accompanying prospectus
contain forward-looking statements that involve risks and uncertainties. These statements relate to future periods, future events or our
future operating or financial performance. All statements other than statements of historical fact, including statements identified by
words such as “may,” “will,” “could,” “expect,” “anticipate,” “continue,”
“plan,” “intend,” “estimate,” “project,” “believe” and similar expressions
or variations, are forward-looking statements. Forward-looking statements include but are not limited to statements regarding our strategy,
future operations, financial condition, results of operations, projected costs, and plans and objectives of management. Actual results
may differ materially from those contemplated by the forward-looking statements due to, among others, the risks and uncertainties described
in this prospectus supplement under “Risk Factors” in the accompanying prospectus, and in the documents incorporated by reference
in this prospectus supplement and the accompanying prospectus. Any forward-looking statement made by us in this prospectus supplement,
the accompanying prospectus and the documents incorporated by reference speaks only as of the date on which the statement is made. We
undertake no obligation to update any forward-looking statement or statements to reflect events or circumstances that occur after the
date on which the statement is made or to reflect the occurrence of unanticipated events.
USE
OF PROCEEDS
We estimate that the net proceeds
to us from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, will
be approximately $8.95 million (or approximately $10.3 million if the underwriters exercise their over-allotment option in full).
We currently intend to use
the net proceeds from this offering for general corporate and working capital purposes, and capital expenditures.
Our management team will have
broad discretion in using the net proceeds to be received by us from this offering.
DIVIDEND
POLICY
We have never declared or
paid any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our
operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the
foreseeable future. In addition, the terms of our current debt arrangements limit our ability to pay dividends. Any future determination
related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our
results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board
of directors may deem relevant.
CAPITALIZATION
The following table sets forth
our cash and cash equivalents and capitalization as of December 31, 2023:
| |
● |
on an actual basis; |
| |
|
|
| |
● |
on a pro forma basis to give effect to the issuance of: (i) the sale of 153,879 shares of common stock in January 2024 for net proceeds of approximately $278,000 under an at-the-market offering Sales Agreement, dated November 22, 2023, by and between us and Leerink Partners LLC (the “ATM Agreement”); and (ii) the receipt of approximately $550,000 from the exercise of warrants to purchase 445,744 shares of our common stock in January 2024; and |
| ● | on
a pro forma, as adjusted basis to reflect the sale of 9,090,910 shares of common stock in this offering at the public offering price
of $1.10 per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, and assuming
no exercise by the underwriter of its over-allotment option. |
You should read this table
along with our unaudited consolidated financial statements and related notes for the nine months ended December 31, 2023 as well as the
other financial information incorporated by reference in this prospectus supplement and the accompanying prospectus.
| | |
Actual | | |
Pro Forma | | |
Pro Forma
As Adjusted | |
| | |
(unaudited; in thousands,
except per-share amounts) | |
| Cash and cash equivalents | |
$ | 2,047 | | |
$ | 2,875 | | |
$ | 11,825 | |
| Stockholders’ equity: | |
| | | |
| | | |
| | |
| Preferred stock, par value $0.001; 5,000 shares authorized and undesignated, actual, pro forma and as adjusted; no shares issued and outstanding, actual, pro forma or pro forma as adjusted | |
| — | | |
| — | | |
| — | |
| Common Stock, $0.001 par value, 50,000 shares authorized and 100,000 shares authorized pro forma; 21,299 shares issued and outstanding, actual; 21,899 shares issued and outstanding, pro forma and 30,990 shares issued and outstanding, pro forma as adjusted | |
| 21 | | |
| 22 | | |
| 31 | |
| Additional paid-in capital | |
| 65,472 | | |
| 66,300 | | |
| 75,241 | |
| Accumulated deficit | |
| (61,648 | ) | |
| (61,648 | ) | |
| (61,648 | ) |
| Total stockholders’ equity | |
$ | 3,845 | | |
$ | 4,674 | | |
$ | 13,624 | |
The pro forma amounts in the
table above reflect the following events subsequent to December 31, 2023:
| ● | on
February 13, 2024, our stockholders approved an increase in our authorized shares of common stock to 100,000,000; |
| ● | in
January 2024, we sold 153,879 shares of common stock for net proceeds of approximately $278,000 under an at-the-market offering
Sales Agreement, dated November 22, 2023, by and between us and Leerink Partners LLC (the “ATM Agreement”); and |
| ● | in
January 2024, we received proceeds of approximately $550,000 from the exercise of warrants to purchase 445,744 shares
of our common stock. |
On February 13, 2024, our
stockholders approved an increase in the number of shares reserved for issuance under the 2017 Plan by 3,000,000 shares.
At December 31, 2023, the
number of shares of common stock outstanding in the table above excludes:
| ● | 767,796
shares of our common stock issuable upon the exercise of warrants with an exercise price of $6.00 per share; |
| ● | 5,449,478
shares of our common stock issuable upon the exercise
of warrants with an exercise price of $6.60 per share; |
| ● | 604,623 shares
of our common stock issuable upon the exercise of warrants with an exercise price of $1.32 per share; |
| ● | 4,921,217
shares of our common stock issuable upon the exercise
of warrants with an exercise price of $1.22 per share; |
| ● | 1,348,314
shares of our common stock issuable upon exercise of pre-funded warrants with an exercise price of $0.01 per share; |
| ● | 3,698,393
shares of our common stock issuable upon exercise of outstanding stock options with a weighted average exercise price of approximately
$3.70 per share; |
| ● | 208,332
shares of our common stock issuable upon vesting of restricted stock units; and |
| ● | 645,974
shares of our common stock reserved for issuance pursuant to future awards under our 2017 Plan. |
DILUTION
If you purchase our common
stock in this offering, you will experience immediate dilution to the extent of the difference between the public offering price per share
you pay in this offering and the net tangible book value (deficit) per share of our common stock immediately after this offering. We calculate
net tangible book value per share by subtracting total liabilities from our total tangible assets and dividing the difference by the number
of shares of common stock outstanding.
Our historical net tangible book value as of December 31, 2023 was
approximately $3.8 million or $0.18 per share of common stock. Subsequent to December 31, 2023, in January 2024, we sold 153,879 shares
of common stock for net proceeds of approximately $278,000 under the ATM Agreement, and we received proceeds of approximately $550,000
from the exercise of warrants to purchase 445,744 shares of our common stock (collectively “the Issuances”). On a pro forma
basis, adjusting for the Issuances, our pro forma, historical net tangible book value as of December 31, 2023 was approximately $4.7 million
or $0.21 per share of common stock After giving effect to the sale in this offering of 9,090,910 shares at a public offering
price of $1.10 and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma,
as adjusted, historical net tangible book value as of December 31, 2023 would have been approximately $13.6 million, or approximately
$0.44 per share. This represents, on an as adjusted, pro forma historical basis, an immediate increase in net tangible book value of approximately
$0.23 per share to existing stockholders and immediate dilution of approximately $0.66 per share to new investors. The following table
illustrates the dilution to new investors on a per-share basis, assuming the underwriters do not exercise their over-allotment option:
| Public offering price per share | |
| | | |
$ | 1.10 | |
| Historical net tangible book value per share as of December 31, 2023 | |
$ | 0.18 | | |
| | |
| Pro forma net tangible book value per share | |
$ | 0.21 | | |
| | |
| Increase in net tangible book value per share attributable to this offering | |
$ | 0.23 | | |
| | |
| Pro forma, as adjusted net tangible book value per share after giving effect to this offering | |
| | | |
$ | 0.44 | |
| Dilution in net tangible book value per share to new investors | |
| | | |
$ | 0.66 | |
If the underwriters exercise
in full their option to purchase 1,321,989 additional shares from us, the as adjusted, pro forma, historical net tangible book value
per share after this offering would be $0.46 per share, the increase in pro forma net tangible, historical book value per share to existing
stockholders would be $0.25 per share and the dilution to new investors purchasing shares in this offering would be $0.64 per share.
The above discussion and tables
exclude:
| ● | 767,796
shares of our common stock issuable upon the exercise of warrants with an exercise price of $6.00 per share; |
| ● | 5,449,478
shares of our common stock issuable upon the exercise
of warrants with an exercise price of $6.60 per share; |
| ● | 604,623 shares
of our common stock issuable upon the exercise of warrants with an exercise price of $1.32 per share and, on a pro forma historical basis,
543,313 shares of our common stock issuable upon the exercise of warrants with an exercise
price of $1.32 per share; |
| ● | 4,921,217
shares of our common stock issuable upon the exercise
of warrants with an exercise price of $1.22 per share and, on a pro forma historical basis, 4,536,783 shares of our common stock issuable
upon the exercise of warrants with an exercise price of $1.22 per share; |
| ● | 1,348,314
shares of our common stock issuable upon exercise of pre-funded warrants with an exercise price of $0.01 per share; |
| ● | 3,698,393
shares of our common stock issuable upon exercise of outstanding stock options with a weighted average exercise price of approximately
$3.70 per share; |
| ● | 208,332
shares of our common stock issuable upon vesting of restricted stock units; and |
| ● | 645,974
shares of our common stock reserved for issuance pursuant to future awards under the 2017 Plan and, on a pro forma historical basis,
3,645,974 shares of our common stock reserved for issuance pursuant to future awards under the 2017 Plan. |
To the extent that additional
shares are issued pursuant to the foregoing, investors purchasing our common stock in this offering will experience further dilution.
DESCRIPTION OF THE SECURITIES WE ARE OFFERING
We are offering 9,090,910 shares of common stock at an offering
price of $1.10 per share.
Common Stock
The material terms and provisions
of our common stock and each other class of our securities that qualifies or limits our common stock are described under the caption “Description
of Capital Stock” starting on page 6 of the accompanying prospectus.
INCORPORATION BY REFERENCE
The SEC’s rules allows
us to incorporate by reference the information contained in documents we file with the SEC. This allows us to disclose important information
to you by referencing those filed documents rather than by including them in the prospectus supplement or the accompanying prospectus.
We have previously filed the
following documents with the SEC and incorporate them by reference into this prospectus supplement:
| |
● |
our Annual Report on Form 10-K for the fiscal year ended March 31, 2023 filed with the SEC on June 26, 2023; |
| |
|
|
| |
● |
our Quarterly Reports on Form 10-Q for the quarters ended June 30, 2023, September 30, 2023, and December 31, 2023, filed with the SEC on August 14, 2023, November 13, 2023, and February 13, 2024, respectively; |
| |
|
|
| |
● |
our Current Reports on
Form 8-K filed with the SEC on May
17, 2023; July 10, 2023; October
5, 2023; and November 22,
2023, January 19, 2024, February
15, 2024, and February 16, 2024; and |
| |
|
|
| |
● |
the description of the Company’s Common Stock contained in the Company’s Registration Statement on Form 8-A (File No. 001-41277) filed on February 9, 2022, including any amendment or report filed for the purpose of updating such description. |
We also are incorporating
by reference any future information filed (rather than furnished) by us with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) after the date of this prospectus supplement and before the completion
or termination of this offering. The most recent information that we file with the SEC automatically updates and supersedes more dated
information.
You may request a free copy
of any of the documents incorporated by reference in this prospectus supplement and the accompanying prospectus (other than exhibits,
unless they are specifically incorporated by reference in the documents) by writing or telephoning us at the following address:
Modular Medical, Inc.
10740 Thornmint Road
San Diego, CA 92127
Attention: Corporate Secretary
(858) 800-3500
Exhibits to the filings will
not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus supplement and the accompanying
prospectus.
UNDERWRITING
Titan Partners Group LLC, a
division of American Capital Partners, LLC, is acting as the representative of the underwriter of the offering (herein referred
to as the “Representative”). We have entered into an underwriting agreement dated February 15, 2024 with the Representative.
Our common stock trades on the Nasdaq Capital Market under the symbol “MODD.”
Subject to the terms and subject
to the conditions contained in the underwriting agreement, we have agreed to sell to the underwriter named below, and the underwriter
has agreed to purchase from us, the number of shares of common stock set forth opposite its name below at the public offering price per
share of common stock, less the underwriting discounts set forth on the cover page of this prospectus supplement:
| Underwriter | |
Number of
Shares | |
| Titan Partners Group LLC, a division of American Capital Partners, LLC | |
| 9,090,910 | |
| Total | |
| 9,090,910 | |
The underwriting agreement
provides that the obligation of the underwriter to purchase the shares of common stock offered by this prospectus supplement and the accompanying
prospectus is subject to certain conditions. The underwriter is obligated to purchase all of the shares of common stock offered hereby
other than those covered by the over-allotment option described below, if any of the shares are purchased. The underwriting agreement
also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may be increased, or the offering
may be terminated. The underwriters are not obligated to purchase the securities covered by the underwriters’ over-allotment option
described below. The underwriters are offering the securities, subject to prior sale, when, as and if issued to and accepted by them,
subject to approval of legal matters by their counsel, and other conditions contained in the underwriting agreement, such as the receipt
by the underwriters of officer’s certificates and legal opinions. The underwriters reserve the right to withdraw, cancel or modify
offers to the public and to reject orders in whole or in part.
We have granted the underwriter
an option to buy up to an additional 1,321,989 shares of common stock from us at the public offering price less the underwriting
discounts and commissions, to cover over-allotments, if any. The underwriter may exercise this option at any time, in whole at any time
or in part from time to time, during the 30-day period after the date of this prospectus supplement. To the extent that the Representative
exercises this option, each of the underwriters will become obligated, subject to conditions, to purchase approximately the same percentage
of these additional shares of common stock as the number of shares of common stock to be purchased by it in the above table bears to the
total number of shares of common stock offered by this prospectus supplement. We will be obligated, pursuant to the option, to sell these
additional shares of common stock to the underwriters to the extent the option is exercised. If this option is exercised in full, the
total offering price to the public will be $11,454,189 and the total net proceeds, before expenses and after the credit to the underwriting
commissions described below, to us will be approximately $10,652,000.
Discounts, Commissions and Expenses
The underwriter proposes to
offer the shares of common stock purchased pursuant to the underwriting agreement to the public at the public offering price set forth
on the cover page of this prospectus supplement and to certain dealers at that price less a concession not in excess of $0.077 per share.
After this offering, the public offering price and concession may be changed by the underwriter. No such change shall change the amount
of proceeds to be received by us as set forth on the cover page of this prospectus supplement.
In connection with the sale
of the common stock to be purchased by the underwriter, the underwriter will be deemed to have received compensation in the form of underwriting
commissions and discounts. The underwriting commissions and discounts will be 7% of the gross proceeds of this offering, or $0.077 per
share of common stock, based on the public offering price per share set forth on the cover page of this prospectus supplement.
We have also agreed to reimburse
the underwriter at closing for legal expenses incurred by the underwriter in connection with the offering up to a maximum amount of $75,000
from this offering as well as all reasonable and accountable out-of-pocket expenses incurred in connection with this offering. Additionally,
we have agreed to pay a non-accountable expense allowance equal to 1% of the gross proceeds from the sale of the securities in this
offering before deducting the underwriting discount and commissions, including, for the avoidance of doubt, the gross proceeds attributable
to shares purchased pursuant to the underwriter’ exercise of its over-allotment option. We have also paid an advance of $15,000
to the Representative, which will be applied against the accountable expenses that will be paid by us to the Representative in connection
with this offering, or the Advance. The Advance will be returned to us to the extent not actually incurred by the Representative in accordance
with Financial Industry Regulation Authority (“FINRA”) Rule 5110(g)(4)(A). We estimate that our total offering expenses
for this offering, net of the underwriting discounts and commissions, will be approximately $250,000.
The following table shows
the underwriting discounts and commissions payable to the underwriter by us in connection with this offering (assuming both the exercise
in full and non-exercise of the over-allotment option to purchase additional shares of common stock that we have granted to the underwriter):
| | |
No Exercise of
Over-Allotment | | |
Full Exercise of
Over-Allotment | |
| | |
Per Share | | |
Total | | |
Per Share | | |
Total | |
| Public offering price | |
$ | 1.100 | | |
$ | 10,00,001 | | |
$ | 1.100 | | |
$ | 11,454,189 | |
| Underwriting discounts and commissions(1) | |
$ | 0.077 | | |
$ | 700,000 | | |
$ | 0.077 | | |
$ | 801,793 | |
| Proceeds to us, before expenses | |
$ | 1.023 | | |
$ | 9,300,001 | | |
$ | 1.023 | | |
$ | 10,652,395 | |
| (1) |
We have agreed to pay the underwriters a commission equal to 7.0% of the aggregate gross proceeds from the sale of the securities in this offering. Additionally, we have agreed to pay a non-accountable expense allowance equal to 1% of the gross proceeds from the sale of the securities in this offering and to reimburse the underwriters for certain expenses in connection with this offering. |
Discretionary Accounts
The underwriters do not intend
to confirm sales of the shares of common stock offered hereby to any accounts over which they have discretionary authority.
Indemnification
Pursuant to the underwriting
agreement, we have agreed to indemnify the underwriter against certain liabilities, including liabilities under the Securities Act, or
to contribute to payments that the underwriter or such other indemnified parties may be required to make in respect of those liabilities.
Insider Participation
An affiliate of one of our
directors and our chief executive officer has indicated interests in purchasing up to an aggregate of 900,000 shares of our common stock
in this offering at the public offering price per share and on the same terms as the other purchasers in this offering. However, because
indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, fewer, or
no shares in this offering to such shareholders and directors, and potential investors may determine to purchase more, fewer, or no shares
in this offering. The underwriters will receive the same underwriting discount with respect to these shares of our common stock as they
will from any other shares of our common stock to be sold to the public in this offering.
Lock-Up Agreements
Without the prior written
consent of the Representative, for a period of 90 days following the date of this prospectus supplement (the “Lock-Up Period”),
we have agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock
or Common Stock Equivalents without the prior written consent of the Representative.
In addition, each of our directors,
officers and holders of 5% or more of any class of the Company’s equity Securities issued and outstanding immediately prior to such
Offering, with the exception of Sio Capital Management, LLC, has entered into a lock-up agreement with the underwriters. Under the lock-up
agreements, without the prior written consent of the Representative, the foregoing persons may not, directly or indirectly, (i) sell,
assign, transfer, pledge, offer to sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option for sale (including any short sale), right or warrant to purchase, lend, establish an open “put equivalent
position” (within the meaning of Rule 16a-1(h) under the Exchange Act), or otherwise dispose of, or enter into any transaction which
is designed to or could be expected to result in the disposition of, any shares of common stock or securities convertible into or exercisable
or exchangeable for any equity securities of the Company (including, without limitation, shares of common stock or any such securities
which may be deemed to be beneficially owned by such persons in accordance with the rules and regulations promulgated by the SEC from
time to time (such shares or securities, the “Beneficially Owned Shares”)), or publicly announce any intention to do any of
the foregoing, other than the exercise of options or warrants so long as there is no sale or disposition of the common stock underlying
such options or warrants during the Lock-Up Period, (ii) enter into any swap, hedge or other agreement or arrangement that transfers in
whole or in part, the economic risk of ownership of any Beneficially Owned Shares, common stock or securities convertible into or exercisable
or exchangeable for any equity securities of the Company, or (iii) engage in any short selling of any Beneficially Owned Shares, common
stock or securities convertible into or exercisable or exchangeable for any equity securities of the Company, whether any such transaction
described in clause (i), (ii) or (iii) above is to be settled by delivery of shares of common stock or such other securities, in cash
or otherwise, for a period of 90 days from the date of this prospectus supplement. This consent may be given at any time without public
notice. These restrictions on future dispositions by our directors and executive officers are subject to certain exceptions for transfers
of Beneficially Owned Shares, including, but not limited to, transfers (i) as a bona fide gift or gifts, (ii) by operation of law, including
pursuant to a qualified domestic order or in connection with a divorce settlement, (iii) to the immediate family of the transferor, (iv)
to any trust for the direct or indirect benefit of such person or the immediate family of the transferor, (v) to any beneficiary of the
transferor pursuant to a will or other testamentary document or applicable laws of descent and (vi) to any corporation, partnership, limited
liability company or other entity all of the beneficial ownership interests of which are held by the transferor or the immediate family
of the transferor.
In
addition, subject to certain limited exceptions, until the one-year anniversary of the closing date of this offering, we will be prohibited
from effecting or entering into an agreement to effect any issuance by us or any of our subsidiaries of common stock or Common Stock Equivalents
(as defined in the Underwriting Agreement) (or a combination of units thereof) involving a Variable Rate Transaction. “Variable
Rate Transaction” means a transaction in which we (i) issue or sell any debt or equity securities that are convertible into, exchangeable
or exercisable for, or include the right to receive, additional shares of our common stock either (A) at a conversion price, exercise
price or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations for the shares of our
common stock at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price
that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of
specified or contingent events directly or indirectly related to our business or the market for the shares of our common stock or (ii)
enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit, whereby we may issue
securities at a future determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless
of whether such agreement is subsequently canceled.
Listing
Our common stock is listed
on The Nasdaq Capital Market under the trading symbol “MODD.”
Electronic Distribution
This prospectus supplement
and the accompanying prospectus may be made available in electronic format on websites or through other online services maintained by
the underwriters or by their affiliates. In those cases, prospective investors may view offering terms online and prospective investors
may be allowed to place orders online. Other than this prospectus supplement and the accompanying prospectus in electronic format, the
information on the underwriters’ websites or our website and any information contained in any other websites maintained by the underwriters
or by us is not part of this prospectus supplement, the accompanying prospectus or the registration statement of which this prospectus
supplement and the accompanying prospectus form a part, has not been approved and/or endorsed by us or the underwriters in their capacity
as underwriters, and should not be relied upon by investors.
Passive Market Making
In connection with this offering,
the underwriters and selling group members may also engage in passive market making transactions in our common stock. Passive market making
consists of displaying bids limited by the prices of independent market makers and effecting purchases limited by those prices in response
to order flow. Rule 103 of Regulation M promulgated by the SEC limits the amount of net purchases that each passive market maker
may make and the displayed size of each bid. Passive market making may stabilize the market price of the shares of common stock at a level
above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.
Price Stabilization, Short Positions and Penalty
Bids
In connection with the offering,
the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate covering transactions and penalty bids
in accordance with Regulation M under the Exchange Act:
Stabilizing transactions permit
bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum.
| ● | Over-allotment
involves sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase, which creates
a syndicate short position. The short position may be either a covered short position or a naked short position. In a covered short position,
the number of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase pursuant to the
over-allotment option. In a naked short position, the number of shares involved is greater than the number of shares that the underwriters
may purchase pursuant to the over-allotment option. The underwriters may close out any covered short position by either exercising the
over-allotment option and/or purchasing shares in the open market. |
| ● | Syndicate
covering transactions involve purchases of the common stock in the open market after the distribution has been completed in order to
cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider,
among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase
shares through the over-allotment option. A naked short position occurs if the underwriters sell more shares than could be covered by
the over-allotment option. This position can only be closed out by buying shares in the open market. A naked short position is more likely
to be created if the underwriters are concerned that there could be downward pressure on the price of the shares in the open market after
pricing that could adversely affect investors who purchase in the offering. |
| ● | Penalty
bids permit the underwriters to reclaim a selling concession from a syndicate member when the common stock originally sold by the syndicate
member is purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions. |
These stabilizing transactions,
syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our common stock or
preventing or retarding a decline in the market price of the common stock. As a result, the price of our common stock may be higher than
the price that might otherwise exist in the open market. These transactions may be discontinued at any time.
Neither we nor the underwriters
make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on
the price of our shares of common stock. In addition, neither we nor the underwriters make any representation that the underwriters will
engage in these transactions or that any transaction, if commenced, will not be discontinued without notice.
Offer restrictions outside the United States
Other than in the United States,
no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus supplement
in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement may not be offered
or sold, directly or indirectly, nor may this prospectus supplement or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus supplement
comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus
supplement. This prospectus supplement does not constitute an offer to sell or a solicitation of an offer to buy any securities offered
by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is unlawful.
Australia
This prospectus supplement
is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian Securities
and Investments Commission and does not purport to include the information required of a disclosure document under Chapter 6D of
the Australian Corporations Act. Accordingly, (i) the offer of the securities under this prospectus supplement is only made to persons
to whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or
more exemptions set out in section 708 of the Australian Corporations Act, (ii) this prospectus supplement is made available in Australia
only to those persons as set forth in clause (i) above, and (iii) the offeree must be sent a notice stating in substance that
by accepting this offer, the offeree represents that the offeree is such a person as set forth in clause (i) above, and, unless permitted
under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree
within 12 months after its transfer to the offeree under this prospectus supplement.
Canada
The securities may be sold
in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National
Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients,
as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale
of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of
applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies
for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that
the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of
the purchaser’s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of
the purchaser’s province or territory for particulars of these rights or consult with a legal advisor. Pursuant to section 3A.3
of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the
disclosure requirements of NI33-105 regarding underwriter conflicts of interest in connection with this offering.
Cayman Islands
No invitation, whether directly
or indirectly, may be made to the public in the Cayman Islands to subscribe for our securities.
European Economic Area — Belgium, Germany,
Luxembourg and Netherlands
The information in this document
has been prepared on the basis that all offers of securities will be made pursuant to an exemption under the Directive 2003/71/EC (“Prospectus
Directive”), as implemented in Member States of the European Economic Area (each, a “Relevant Member State”), from the
requirement to produce a prospectus for offers of securities.
An offer to the public of
securities has not been made, and may not be made, in a Relevant Member State except pursuant to one of the following exemptions under
the Prospectus Directive as implemented in that Relevant Member State:
| ● | to
legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate
purpose is solely to invest in securities; |
| ● | to
any legal entity that has two or more of (i) an average of at least 250 employees during its last fiscal year; (ii) a total
balance sheet of more than €43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii) an
annual net turnover of more than €50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements); |
| ● | to
fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article 2(1)(e) of the Prospectus
Directive) subject to obtaining the prior consent of the Company or any underwriter for any such offer; or |
| ● | in
any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities
shall result in a requirement for the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive. |
France
This document is not being
distributed in the context of a public offering of financial securities (offre au public de titres financiers) in France within the meaning
of Article L.411-1 of the French Monetary and Financial Code (Code Monétaire et Financier) and Articles 211-1 et
seq. of the General Regulation of the French Autorité des marchés financiers (“AMF”). The securities have not
been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.
This document and any other
offering material relating to the securities have not been, and will not be, submitted to the AMF for approval in France and, accordingly,
may not be distributed or caused to distributed, directly or indirectly, to the public in France.
Such offers, sales and distributions
have been and shall only be made in France to (i) qualified investors (investisseurs qualifiés) acting for their own account,
as defined in and in accordance with Articles L.411-2-II-2° and D.411-1 to D.411-3, D.744-1, D.754-1 ;and D.764-1 of
the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified investors
(cercle restreint d’investisseurs) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2°
and D.411-4, D.744-1, D.754-1; and D.764-1 of the French Monetary and Financial Code and any implementing regulation.
Pursuant to Article 211-3 of
the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly)
to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3 of
the French Monetary and Financial Code.
Ireland
The information in this document
does not constitute a prospectus under any Irish laws or regulations and this document has not been filed with or approved by any Irish
regulatory authority as the information has not been prepared in the context of a public offering of securities in Ireland within the
meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the “Prospectus Regulations”). The securities
have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering,
except to (i) qualified investors as defined in Regulation 2(l) of the Prospectus Regulations and (ii) fewer than
100 natural or legal persons who are not qualified investors.
Israel
The securities offered by
this prospectus supplement have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor have such
securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel,
absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering or publishing
the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion
as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities offered
by this prospectus supplement is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities
laws and regulations.
Italy
The offering of the securities
in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Società
e la Borsa, “CONSOB” pursuant to the Italian securities legislation and, accordingly, no offering material relating to the
securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer within the meaning of
Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998 (“Decree No. 58”), other than:
| ● | to Italian qualified
investors, as defined in Article 100 of Decree no.58 by reference to Article 34-ter of CONSOB Regulation
no. 11971 of 14 May 1999 (“Regulation no. 1197l”) as amended (“Qualified Investors”);
and |
| ● | in
other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree No. 58 and Article 34-ter of
Regulation No. 11971 as amended. |
Any offer, sale or delivery
of the securities or distribution of any offer document relating to the securities in Italy (excluding placements where a Qualified Investor
solicits an offer from the issuer) under the paragraphs above must be:
| ● | made
by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative Decree
No. 385 of 1 September 1993 (as amended), Decree No. 58, CONSOB Regulation No. 16190 of 29 October 2007 and any other
applicable laws; and |
| ● | in
compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws. |
Any subsequent distribution
of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules provided under Decree No.
58 and the Regulation No. 11971 as amended, unless an exception from those rules applies. Failure to comply with such rules may result
in the sale of such securities being declared null and void and in the liability of the entity transferring the securities for any damages
suffered by the investors.
Japan
The securities have not been
and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948),
as amended (the “FIEL”) pursuant to an exemption from the registration requirements applicable to a private placement of securities
to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of the FIEL and the regulations
promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit
of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional Investor who acquires securities may
not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities
is conditional upon the execution of an agreement to that effect.
Portugal
This document is not being
distributed in the context of a public offer of financial securities (oferta pública de valores mobiliários) in Portugal,
within the meaning of Article 109 of the Portuguese Securities Code (Código dos Valores Mobiliários). The securities
have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document and any
other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market Commission
(Comissăo do Mercado de Valores Mobiliários) for approval in Portugal and, accordingly, may not be distributed or caused
to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify as a
public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to persons
who are “qualified investors” (as defined in the Portuguese Securities Code). Only such investors may receive this document
and they may not distribute it or the information contained in it to any other person.
Sweden
This document has not been,
and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this document
may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances that are deemed not to
require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel med finansiella instrument).
Any offering of securities in Sweden is limited to persons who are “qualified investors” (as defined in the Financial Instruments
Trading Act). Only such investors may receive this document and they may not distribute it or the information contained in it to any other
person.
Switzerland
The securities may not be
publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (“SIX”) or on any other stock exchange or
regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses
under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of
the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document
nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly available in Switzerland.
Neither this document nor
any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory authority.
In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market
Supervisory Authority (FINMA).
This document is personal
to the recipient only and not for general circulation in Switzerland.
United Arab Emirates
Neither this document nor
the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental
authority in the United Arab Emirates, nor has the Company received authorization or licensing from the Central Bank of the United Arab
Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within the United Arab Emirates.
This document does not constitute and may not be used for the purpose of an offer or invitation. No services relating to the securities,
including the receipt of applications and/or the allotment or redemption of such shares, may be rendered within the United Arab Emirates
by the Company.
No offer or invitation to
subscribe for securities is valid or permitted in the Dubai International Financial Centre.
United Kingdom
Neither the information in
this document nor any other document relating to the offer has been delivered for approval to the Financial Conduct Authority in the United
Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended (“FSMA”)
has been published or is intended to be published in respect of the securities. This document is issued on a confidential basis to “qualified
investors” (within the meaning of section 86(7) of FSMA) in the United Kingdom, and the securities may not be offered or sold
in the United Kingdom by means of this document, any accompanying letter or any other document, except in circumstances which do not require
the publication of a prospectus pursuant to section 86(1) FSMA. This document should not be distributed, published or reproduced,
in whole or in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom.
Any invitation or inducement
to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities
has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom
in circumstances in which section 21(1) of FSMA does not apply to the Company.
In the United Kingdom, this
document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments
falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions)
Order 2005 (“FPO”), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high
net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together
“relevant persons”). The investments to which this document relates are available only to, and any invitation, offer or agreement
to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document
or any of its contents.
LEGAL
MATTERS
The validity of the shares
of common stock offered hereby will be passed upon for us by Lucosky Brookman LLP, Woodbridge, New Jersey. Certain legal matters in connection
with this offering will be passed upon for the underwriters by Blank Rome LLP, New York, New York.
EXPERTS
The consolidated balance sheets
as of March 31, 2023 and March 31, 2022 and the related consolidated statements of operations, stockholders’ equity, and cash flows
included in our Annual Report on Form 10-K for the years ended March 31, 2023 and March 31, 2022 and incorporated herein by reference
have been audited by Farber Hass Hurley LLP, our independent registered public accounting firm. The report therein contains an explanatory
paragraph which describes the conditions that raise substantial doubt about the Company’s ability to continue as a going concern.
WHERE
YOU CAN FIND MORE INFORMATION
This prospectus supplement
and the accompanying prospectus are part of the registration statement that we have filed with the SEC and omit certain information contained
in the registration statement. We have also filed exhibits with the registration statement that are excluded from this prospectus supplement
and the accompanying prospectus, and you should refer to the applicable exhibit for a complete description of any statement referring
to any contract or other document. We file annual, quarterly and current reports, proxy statements and other information with the SEC.
Such filings are made available on our Internet website, www.modular-medical.com , as soon as reasonably practicable after they are filed
with, or furnished to, the SEC. Our website and the information contained on that site, or connected to that site, are not incorporated
into and are not a part of this prospectus supplement or the accompanying prospectus. The SEC maintains an Internet site, www.sec.gov,
which contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC,
including the Company.
PROSPECTUS
MODULAR MEDICAL, INC.
$50,000,000
COMMON STOCK
PREFERRED STOCK
DEBT SECURITIES
WARRANTS
UNITS
This prospectus will allow
us to issue, from time to time at prices and on terms to be determined at or prior to the time of the offering, up to $50,000,000 of any
combination of the securities described in this prospectus, either individually or in units. We may also offer common stock or preferred
stock upon conversion of or exchange for the debt securities; and common stock or preferred stock or debt securities upon the exercise
of warrants.
This prospectus describes
the general terms of these securities and the general manner in which these securities will be offered. We will provide you with the specific
terms of any offering in one or more supplements to this prospectus. The prospectus supplements will also describe the specific manner
in which these securities will be offered and may also supplement, update or amend information contained in this document. You should
read this prospectus and any prospectus supplement, as well as any documents incorporated by reference into this prospectus or any prospectus
supplement, carefully before you invest.
Our securities may be sold
directly by us to you, through agents designated from time to time or to or through underwriters or dealers. For additional information
on the methods of sale, you should refer to the section entitled “Plan of Distribution” in this prospectus and in the applicable
prospectus supplement. If any underwriters or agents are involved in the sale of our securities with respect to which this prospectus
is being delivered, the names of such underwriters or agents and any applicable fees, commissions or discounts and over-allotment options
will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds that we expect to receive
from such sale will also be set forth in a prospectus supplement.
Our common stock is listed
on the Nasdaq Capital Market, under the symbol “MODD.” On April 1, 2022, the last reported sale price of our common stock
on the Nasdaq Capital Market was $4.25 per share.
Investing in our securities
involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks that we have
described on page 2 of this prospectus under the caption “Risk Factors.” We may include specific risk factors in supplements
to this prospectus under the caption “Risk Factors.” This prospectus may not be used to sell our securities unless accompanied
by a prospectus supplement.
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus
is April 19, 2022
TABLE OF CONTENTS
ABOUT THIS PROSPECTUS
This prospectus is part of
a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a “shelf” registration
process. Under this shelf registration process, we may offer shares of our common stock, preferred stock, various series of debt securities
or warrants to purchase common stock or preferred stock, either individually or in units, in one or more offerings, with a total value
of up to $50,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type
or series of securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the
terms of that offering.
This prospectus does not contain
all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you
should refer to the registration statement, including its exhibits. The prospectus supplement may also add, update or change information
contained or incorporated by reference in this prospectus. However, no prospectus supplement will offer a security that is not registered
and described in this prospectus at the time of its effectiveness. This prospectus, together with the applicable prospectus supplements
and the documents incorporated by reference into this prospectus, includes all material information relating to the offering of securities
under this prospectus. You should carefully read this prospectus, the applicable prospectus supplement, the information and documents
incorporated herein by reference and the additional information under the heading “Where You Can Find More Information” before
making an investment decision.
You should rely only on the
information we have provided or incorporated by reference in this prospectus or any prospectus supplement. We have not authorized anyone
to provide you with information different from that contained or incorporated by reference in this prospectus. No dealer, salesperson
or other person is authorized to give any information or to represent anything not contained or incorporated by reference in this prospectus.
You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby,
but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus
or any prospectus supplement is accurate only as of the date on the front of the document and that any information we have incorporated
herein by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this
prospectus or any sale of a security.
We further note that the representations,
warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in
the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose
of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you.
Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations,
warranties and covenants should not be relied on as accurately representing the current state of our affairs.
This prospectus may not be
used to consummate sales of our securities, unless it is accompanied by a prospectus supplement. To the extent there are inconsistencies
between any prospectus supplement, this prospectus and any documents incorporated by reference, the document with the most recent date
will control.
Unless the context otherwise
requires, “Modular Medical,” “the Company,” “the Registrant,” “we,” “us,”
“our” and similar terms refer to Modular Medical, Inc.
PROSPECTUS SUMMARY
This
summary highlights selected information that is presented in greater detail elsewhere in this prospectus or incorporated by reference
in this prospectus. Because it is only a summary, it does not contain all of the information you should consider before investing in our
securities, and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere
in this prospectus. Before you decide whether to purchase our securities, you should read this entire prospectus, the applicable prospectus
supplement and any related free writing prospectus carefully, including the risks of investing in our securities discussed under the heading
“Risk Factors” contained in the applicable prospectus supplement and any related free writing prospectus, and under similar
headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information
incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of
which this prospectus is a part.
Overview
Modular Medical is a development
stage medical device company focused on the design, development, and commercialization of an innovative insulin pump using modernized
technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, our MODD1 product
candidate, or MODD1, the Company seeks to fundamentally alter the trade-offs between cost and complexity and access to the higher standards
of care that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription,
reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated
“super users” and expand the category into the mass market. The product candidate seeks to serve both the type 1 and the rapidly
growing, especially in terms of device adoption, type 2 diabetes markets.
Our team has substantial knowledge
of the diabetes industry and experience in developing, obtaining regulatory authorization for, and bringing insulin pumps to market. Based
on this experience, we believe that our innovative insulin pump, using a new and proprietary method of pumping insulin, can address most
or all of these shortcomings. It provides a state-of-the-art insulin pump capable of both basal (steady flow) and bolus (mealtime dosing)
insulin disbursement. It also has been designed considering a natural migration path to multi-chamber/multi-liquid pumps, potentially
offering an exciting array of new therapies to patients with diabetes and other conditions.
Our goal is to become the
leader in expanding access to insulin pump technology to a wider portion of diabetes sufferers and provide not just care for the super
users, but “diabetes care for the rest of us.”
The MODD1 is a high-precision,
first-line pump that we believe represents the best choice for new pump patients because it is easy to afford, easy to learn, easy to
use, and has a revolutionary design and technology that enable precision with low-cost manufacture and high reproducibility.
Corporate Information
Our principal executive offices
are located at 16772 West Bernardo Drive, San Diego, CA 92127 and our telephone number is (858) 800-3500. We maintain a website at www.modular-medical.com
to which we regularly post copies of our press releases, as well as additional information about us. Our filings with the Securities and
Exchange Commission, or SEC, will be available free of charge through the website as soon as reasonably practicable after being electronically
filed with or furnished to the SEC. Information contained on, or accessible through, our website does not constitute a part of this prospectus
or our other filings with the SEC, and you should not consider any information contained on, or that can be accessed through, our website
as part of this prospectus or in deciding whether to purchase our Units.
All brand names or trademarks
appearing in this prospectus are the property of their respective holders. Use or display by us of other parties’ trademarks, trade
dress, or products in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of,
us by the trademark or trade dress owners.
RISK FACTORS
Investment
in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. You should carefully consider
the risk factors incorporated by reference to our Registration Statement on Form S-1, filed with the SEC on February 9, 2022, as amended,
our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K we file after
the date of this prospectus, and all other information contained or incorporated by reference into this prospectus, as updated by our
subsequent filings under the Exchange Act, and the risk factors and other information contained in the applicable prospectus supplement
before acquiring any of such securities. The occurrence of any of these risks might cause you to lose all or part of your investment in
the offered securities.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
prospectus, any accompanying prospectus supplement, and the documents incorporated by reference herein and therein, include forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the
Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact contained in
this prospectus, any accompanying prospectus supplement, or the documents incorporated by reference herein or therein, including statements
regarding estimates, future events, our future financial performance, business strategy and plans and objectives of management for future
operations, including with respect to us specifically and the cancer diagnostics industry in general, are forward-looking statements.
We have attempted to identify estimates and forward-looking statements by terminology including “aims,” “anticipates,”
“believes,” “can,” “continue,” “could,” “estimates,” “expects,”
“goal,” “intends,” “may,” “plans,” “potential,” “predicts,” “seeks,”
“should,” “suggests,” “targets” or “will” or the negative of these terms or other comparable
terminology. Although we do not make estimates or forward-looking statements unless we believe we have a reasonable basis for doing so,
we cannot guarantee their accuracy. Our estimates and forward-looking statements are based on our current assumptions and expectations
about future events and trends, which affect or may affect our business, strategy, operations or financial performance. These statements
are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause our or our industry’s
actual results, levels of activity, performance or achievements to vary materially from those expressed or implied by these estimates
and forward-looking statements.
Factors
that could cause or contribute to such differences in results and outcomes include, but are not limited to, those discussed under the
section entitled “Risk Factors” in this prospectus, any accompanying prospectus supplement, and in any documents incorporated
by reference herein and therein. Readers should carefully review this information as well as other risks and uncertainties described in
other filings with the SEC that we may make after the filing date of this prospectus. See the information included under the heading “Where
You Can Find More Information.”
Moreover,
we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for us to
predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination
of factors, may cause our actual results to differ materially from those contained in any estimates or forward-looking statements. All
estimates and forward-looking statements speak only as of the date they were made, and, except to the extent required by applicable law
or regulation, we undertake no obligation to update or to review any estimate and/or forward-looking statement. In light of these risks
and uncertainties, we cannot assure you that the estimates or forward-looking statements contained in this prospectus, any accompanying
prospectus supplement, or the documents incorporated by reference herein or therein, will in fact occur. You should not place undue reliance
on these estimates and forward-looking statements.
We
qualify all of our forward-looking statements by these cautionary statements.
USE OF PROCEEDS
We
intend to use the net proceeds we receive from the sale of our securities offered by us hereby for working capital and other general corporate
purposes.
We
may set forth additional information regarding the use of proceeds from the sale of securities we offer under this prospectus in a prospectus
supplement relating to the specific offering. We have not determined the amount of net proceeds to be used specifically for the foregoing
purposes. As a result, our management will have broad discretion in the allocation of net proceeds.
GENERAL DESCRIPTION OF SECURITIES
We,
directly or through agents, dealers or underwriters designated from time to time, may offer, issue and sell, together or separately, in
one or more offerings, up to $50,000,000 in the aggregate, inclusive of any exercise price thereof, of:
| |
● |
shares of our common stock, par value $0.001 per share; |
| |
● |
shares of our Preferred stock, par value $0.001 per share; |
| |
● |
warrants to purchase shares of our common stock; |
| |
● |
units comprised of one or more shares of common stock and warrants in any combination; or |
| |
● |
any combination of the foregoing, each on terms to be determined at the time of sale. |
The
common stock, preferred stock, debt securities, warrants and units are collectively referred to herein as the securities. This prospectus
provides you with a general description of the securities we may offer. Each time we offer securities under this prospectus, we will,
to the extent required by law, provide you with a prospectus supplement that will contain specific information about the terms of the
offering. The prospectus supplement may also add, update or change information in this prospectus. The securities involve various risks
that we will describe in the section entitled “Risk Factors” that will be included in each prospectus supplement. For more
details, see the information included under the heading “About this Prospectus.”
DESCRIPTION OF CAPITAL
STOCK
We
are authorized to issue up to 50,000,000 shares of Common Stock, par value $0.001 per share and up to 5,000,000 shares of preferred stock,
par value $0.001 per share. As of April 1, 2022, we had 10,461,898 shares of our Common Stock outstanding.
The
following description is a summary, does not purport to be complete and is subject to and qualified in its entirety by reference to our
amended and restated articles of incorporation, and our amended bylaws, each of which is incorporated herein by reference and are exhibits
to the registration statement of which this prospectus forms a part. We encourage you to read our amended and restated articles of incorporation,
our amended bylaws and the applicable provisions of the Nevada Revised Statutes (the “NRS”) for additional information.
Common Stock
Each
holder of our Common Stock is entitled to a pro rata share of any cash distributions made to shareholders, including any dividend payments.
The holders of our Common Stock are entitled to one vote for each share or record on all matters to be voted on by our shareholders. There
is no cumulative voting with respect to the election of our directors or any other matter. Therefore, under our charter documents, the
holders of more than 50% of the shares voted for the election of those directors can elect all of the directors. Our board of directors
currently are elected as a single class. Our board of directors may from time to time declare dividends on our outstanding shares. In
the event of our liquidation, dissolution or winding up, the holders of our Common Stock are entitled to share ratably in all assets remaining
available for distribution to them after payment of our liabilities and after provision has been made for each class of stock, if any,
having any preference in relation to our Common Stock. Holders of shares of our Common Stock have no conversion, preemptive or other subscription
rights, and there are no redemption provisions applicable to our Common Stock.
Preferred Stock
Our
articles of incorporation provide that our board of directors has the right in its discretion to issue preferred stock without approval
of our shareholders and to set the series, classes, rights, privileges and preferences of our preferred stock or any classes, or series
thereof without approval. In the event of a hostile takeover, the board of directors could potentially use this preferred stock to preserve
control.
Outstanding Common Stock Warrants
As
of April 1, 2022, we had the following warrants outstanding to purchase shares of our common stock:
| |
● |
4,011,276 at an exercise price of $6.60 per share; and |
| |
● |
767,796 at an exercise price of $6.00 per share. |
Outstanding Common Stock Options
As
of April 1, 2022, we had 1,650,735 outstanding options to purchase shares of our Common Stock at a weighted average exercise price of
$6.58 per share. In addition, on April 1, 2022, we had 989,435 shares available for future issuance under our Amended 2017 Equity Incentive
Plan.
Transfer Agent and Registrar
The
transfer agent and registrar for our Common Stock is Colonial Stock Transfer Company, Inc., 7840 S 700 E, Sandy, UT 84070. Its telephone
number is 801-355-5740.
Stock Market Listing
Our
common stock is listed on The Nasdaq Capital Market under the symbol “MODD.”
DESCRIPTION OF DEBT
SECURITIES
The
following description, together with the additional information we include in any applicable prospectus supplements, summarizes the material
terms and provisions of the debt securities that we may offer under this prospectus. While the terms we have summarized below will apply
generally to any future debt securities we may offer pursuant to this prospectus, we will describe the particular terms of any debt securities
that we may offer in more detail in the applicable prospectus supplement. If we so indicate in a prospectus supplement, the terms of any
debt securities offered under such prospectus supplement may differ from the terms we describe below, and to the extent the terms set
forth in a prospectus supplement differ from the terms described below, the terms set forth in the prospectus supplement shall control.
We
may sell from time to time, in one or more offerings under this prospectus, debt securities, which may be senior or subordinated. We will
issue any such senior debt securities under a senior indenture that we will enter into with a trustee to be named in the senior indenture.
We will issue any such subordinated debt securities under a subordinated indenture, which we will enter into with a trustee to be named
in the subordinated indenture. We use the term “indentures” to refer to either the senior indenture or the subordinated indenture,
as applicable. The indentures will be qualified under the Trust Indenture Act of 1939, as in effect on the date of the indenture. We use
the term “debenture trustee” to refer to either the trustee under the senior indenture or the trustee under the subordinated
indenture, as applicable.
The
following summaries of material provisions of the senior debt securities, the subordinated debt securities and the indentures are subject
to, and qualified in their entirety by reference to, all the provisions of the indenture applicable to a particular series of debt securities.
General
Each
indenture will provide that debt securities may be issued from time to time in one or more series and may be denominated and payable in
foreign currencies or units based on or relating to foreign currencies. Neither indenture will limit the amount of debt securities that
may be issued thereunder, and each indenture will provide that the specific terms of any series of debt securities shall be set forth
in, or determined pursuant to, an authorizing resolution and/or a supplemental indenture, if any, relating to such series.
We
will describe in each prospectus supplement the following terms relating to a series of debt securities:
| |
● |
the title or designation; |
| |
● |
the aggregate principal amount and any limit on the amount that may be issued; |
| |
● |
the currency or units based on or relating to currencies in which debt securities of such series are denominated and the currency or units in which principal or interest or both will or may be payable; |
| |
● |
whether we will issue the series of debt securities in global form, the terms of any global securities and who the depositary will be; |
| |
● |
the maturity date and the date or dates on which principal will be payable; |
| |
● |
the interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the date or dates interest will be payable and the record dates for interest payment dates or the method for determining such dates; |
| |
● |
whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; |
| |
● |
the terms of the subordination of any series of subordinated debt; |
| |
● |
the place or places where payments will be payable; |
| |
● |
our right, if any, to defer payment of interest and the maximum length of any such deferral period; |
| |
● |
the date, if any, after which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional redemption provisions; |
| |
● |
the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund provisions or otherwise, to redeem, or at the holder’s option to purchase, the series of debt securities; |
| |
● |
whether the indenture will restrict our ability to pay dividends, or will require us to maintain any asset ratios or reserves |
| |
● |
whether we will be restricted from incurring any additional indebtedness; |
| |
● |
a discussion on any material or special U.S. federal income tax considerations applicable to a series of debt securities; |
| |
● |
the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; and |
| |
● |
any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities. |
We
may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of
acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax
considerations and other special considerations applicable to any of these debt securities in the applicable prospectus supplement.
Conversion or Exchange Rights
We
will set forth in the prospectus supplement the terms, if any, on which a series of debt securities may be convertible into or exchangeable
for our common stock or our other securities. We will include provisions as to whether conversion or exchange is mandatory, at the option
of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities
that the holders of the series of debt securities receive would be subject to adjustment.
Information Concerning the Debenture Trustee
The
debenture trustee, other than during the occurrence and continuance of an event of default under the applicable indenture, undertakes
to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the
debenture trustee under such indenture must use the same degree of care as a prudent person would exercise or use in the conduct of his
or her own affairs. Subject to this provision, the debenture trustee is under no obligation to exercise any of the powers given it by
the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs,
expenses and liabilities that it might incur.
Payment and Paying Agents
Unless
we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest
payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business
on the regular record date for the interest.
We
will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated
by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check which
we will mail to the holder. Unless we otherwise indicate in a prospectus supplement, we will designate the corporate trust office of the
debenture trustee in the City of New York as our sole paying agent for payments with respect to debt securities of each series. We will
name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular
series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.
All
money we pay to a paying agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt securities
which remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to
us, and the holder of the security thereafter may look only to us for payment thereof.
Governing Law
The
indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the
extent that the Trust Indenture Act is applicable.
Subordination of Subordinated Debt Securities
Our
obligations pursuant to any subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to
certain of our other indebtedness to the extent described in a prospectus supplement. The subordinated indenture does not limit the amount
of senior indebtedness we may incur. It also does not limit us from issuing any other secured or unsecured debt.
DESCRIPTION OF WARRANTS
We
may offer, sell and issue, from time to time, warrants to purchase shares of our common stock. The warrants may be issued independently
or together with shares of our common stock and may be attached to or separate from the shares of our common stock. If we issue warrants,
they will be evidenced by warrant agreements or warrant certificates issued under one or more warrant agreements, which will be contracts
between us and/or a bank or trust company, as warrant agent, and the holders of the warrants or an agent for the holders of the warrants,
all as shall be set forth in the prospectus supplement relating to warrants being offered pursuant to such prospectus supplement. The
forms of warrant agreements or warrant certificates, as applicable, relating to the warrants will be filed as exhibits to the registration
statement of which this prospectus is part and/or will be incorporated by reference from reports that we file with the SEC.
The
following summary of material provisions of the warrants and warrant agreements are subject to, and qualified in their entirety by reference
to, all of the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants. We urge you
to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete warrant agreements and warrant
certificates that contain the terms of the warrants.
Whenever
warrants are to be issued and sold pursuant to this prospectus, we will file a prospectus supplement relating to that offer and sale which
will specify (in each case as applicable):
| |
● |
the number of shares of common stock purchasable upon exercise of the warrants and the exercise price at which such number of shares may be purchased upon exercise; |
| |
● |
the price or prices at which the warrants will be issued; |
| |
● |
the provisions, if any, for changes to or adjustments in the exercise price; |
| |
● |
the provisions, if any, for call rights or put rights relating to the warrants or the underlying shares of common stock; |
| |
● |
the date on which the right to exercise the warrants shall commence and the date on which the right will expire; |
| |
● |
if applicable, the number of warrants issued with each share of our common stock; |
| |
● |
if applicable, the date on and after which the warrants and the related common stock will be separately transferable; and |
| |
● |
any other terms of the warrants, including terms, procedures and limitations relating to the exchange, exercise and settlement of the warrants. |
Until any warrants to purchase
common stock are exercised, the holders of warrants will not be entitled, by virtue of being such holders, to vote, consent, receive dividends,
receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or any other matter, or to
exercise any rights whatsoever as our stockholders.
Each warrant will entitle
the holder to purchase for cash such shares of our common stock at such exercise price as shall be in each case be set forth in, or be
determinable as set forth in, the prospectus supplement relating to the warrants offered thereby. Warrants may be exercised at any time
up to the close of business on the expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After
the close of business on the expiration date, unexercised warrants will become void.
The warrants may be exercised
as set forth in the prospectus supplement relating to the warrants offered. Upon receipt of payment and the warrant certificate properly
completed and duly executed at the Company or the corporate trust office of the warrant agent, as applicable, or any other office indicated
in the prospectus supplement, we will, as soon as practicable, forward the shares of our common stock purchasable upon such exercise.
If less than all of the warrants represented by such warrant certificate are exercised, a new warrant certificate will be issued for the
remaining warrants.
DESCRIPTION OF UNITS
We may issue units comprised
of one or more of the other securities described in this prospectus in any combination from time to time. Each unit will be issued so
that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights
and obligations of a holder of each included security. If we issue units, they will be evidenced by unit agreements or unit certificates
issued under one or more unit agreements, which will be contracts between us and the holders of the units or an agent for the holders
of the units. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or
transferred separately, at any time or at any time before a specified date. The forms of unit agreements or unit certificates, as applicable,
relating to the units will be filed as exhibits to the registration statement that includes this prospectus, or as an exhibit to a filing
with the SEC that is incorporated by reference into this prospectus.
PLAN OF DISTRIBUTION
We may sell our securities
from time to time in any manner permitted by the Securities Act, including any one or more of the following ways:
| |
● |
to investors through agents; |
| |
● |
to or through underwriters; |
| |
● |
to or through broker-dealers (acting as agent or principal); |
| |
● |
in ordinary brokerage transactions and transactions in which a broker solicits purchasers; |
| |
● |
in privately negotiated transactions; |
| |
● |
in “at the market” offerings, within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise; and/or |
| |
● |
directly to purchasers, through a specific bidding or auction process or otherwise. |
The securities may be sold
at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, at prices relating to the prevailing
market prices or at negotiated prices.
Offers to purchase offered
securities may be solicited by agents designated by us from time to time. Any agent involved in the offer or sale of the offered securities
in respect of which this prospectus is delivered will be named, and any commissions payable by us will be set forth, in the applicable
prospectus supplement. Unless otherwise set forth in the applicable prospectus supplement, any agent will be acting on a reasonable best
efforts basis for the period of its appointment. Any agent may be deemed to be an underwriter, as that term is defined in the Securities
Act, of the offered securities so offered and sold.
We will set forth in a prospectus
supplement the terms of the offering of our securities, including:
| |
● |
the name or names of any agents, underwriters or dealers; |
| |
|
|
| |
● |
the purchase price of our securities being offered and the proceeds we will receive from the sale; |
| |
|
|
| |
● |
any over-allotment options under which underwriters may purchase additional securities from us; |
| |
|
|
| |
● |
any agency fees or underwriting discounts and commissions and other items constituting agents’ or underwriters’ compensation; |
| |
|
|
| |
● |
the public offering price; |
| |
|
|
| |
● |
any discounts or concessions allowed or reallowed or paid to dealers; and |
| |
|
|
| |
● |
any securities exchanges on which such securities may be listed. |
If offered securities are
sold to the public by means of an underwritten offering, either through underwriting syndicates represented by managing underwriters
or directly by the managing underwriters, we will execute an underwriting agreement with an underwriter or underwriters, and the names
of the specific managing underwriter or underwriters, as well as any other underwriters, will be set forth in the applicable prospectus
supplement. In addition, the terms of the transaction, including commissions, discounts and any other compensation of the underwriters
and dealers, if any, will be set forth in the applicable prospectus supplement, which prospectus supplement will be used by the underwriters
to make resales of the offered securities. If underwriters are utilized in the sale of the offered securities, the offered securities
will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions, including:
| |
● |
transactions on the Nasdaq Capital Market or any other organized market where the securities may be traded; |
| |
|
|
| |
● |
in the over-the-counter market; |
| |
|
|
| |
● |
in negotiated transactions; or |
| |
|
|
| |
● |
under delayed delivery contracts or other contractual commitments. |
We may grant to the underwriters
options to purchase additional offered securities to cover over-allotments, if any, at the public offering price with additional underwriting
discounts or commissions, as may be set forth in the applicable prospectus supplement. If we grant any over-allotment option, the terms
of the over-allotment option will be set forth in the applicable prospectus supplement.
We may authorize agents or
underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price
set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in
the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in
the prospectus supplement.
We may indemnify agents, underwriters
and dealers against specified liabilities, including liabilities incurred under the Securities Act, or to contribution by us to payments
they may be required to make in respect of such liabilities. Agents, underwriters or dealers, or their respective affiliates, may be customers
of, engage in transactions with or perform services for us or our respective affiliates, in the ordinary course of business.
Unless otherwise specified
in the applicable prospectus supplement, each class or series of securities will be a new issue with no established trading market, other
than our common stock, which is traded on the Nasdaq Capital Market. We may elect to list any other class or series of securities on any
exchange and, in the case of our common stock, on any additional exchange. However, unless otherwise specified in the applicable prospectus
supplement, we will not be obligated to do so. It is possible that one or more underwriters may make a market in a class or series of
securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We cannot
give any assurance as to the liquidity of the trading market for any of the offered securities.
Any underwriter may engage
in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange
Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids
to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other
short-covering transactions involve purchases of the securities, either through exercise of the over-allotment option or in the open market
after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from
a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions.
Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue
any of the activities at any time.
To comply with the securities
laws of certain states, if applicable, the securities offered by this prospectus will be offered and sold in those states only through
registered or licensed brokers or dealers.
In compliance with guidelines
of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or
independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable
prospectus supplement.
LEGAL MATTERS
Lucosky Brookman LLP will
pass upon the validity of the issuance of the securities to be offered by this prospectus.
EXPERTS
Farber Hass Hurley LLP, an
independent registered public accounting firm, has audited our consolidated balance sheets as of March 31, 2021 and March 31, 2020, and
the related consolidated statements of operations, stockholders’ deficit, and cash flows for the fiscal years then ended, which
report is incorporated by reference in this prospectus. We have incorporated by reference our financial statements in this prospectus
and in this registration statement in reliance on the report of Farber Hass Hurley LLP given on their authority as experts in accounting
and auditing.
INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE
The SEC allows us to “incorporate”
into this prospectus information that we file with the SEC in other documents. This means that we can disclose important information to
you by referring to other documents that contain that information. Any information that we incorporate by reference into this prospectus
is considered part of this prospectus.
Information contained in this
prospectus and information that we file with the SEC in the future and incorporate by reference in this prospectus automatically modifies
and supersedes previously filed information, including information in previously filed documents or reports that have been incorporated
by reference in this prospectus, to the extent the new information differs from or is inconsistent with the old information. Any statement
so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed
not to constitute a part of this prospectus. For more information, see “About this Prospectus.”
We incorporate by reference,
as of their respective dates of filing, the documents listed below that we have filed with the SEC and any additional documents that we
may file in the future with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including any documents filed
after the date on which the registration statement of which this prospectus is a part is initially filed until the offering of the security
covered by this prospectus has been completed, other than, in each case, documents or information deemed to have been “furnished”
and not “filed” in accordance with SEC rules:
| |
● |
our Annual Report on Form 10-K for the fiscal year ended March 31, 2021 filed with the SEC on June 29, 2021; |
| |
|
|
| |
● |
our Quarterly Reports on
Form 10-Q for the quarters ended June 30, 2021, September 30, 2021 and December 31, 2021, filed with the SEC on August 16, 2021,
November 12, 2021 and February 14, 2022, respectively; |
| |
|
|
| |
● |
our Current Reports on
Form 8-K filed with the SEC on May 12, 2021, May 24, 2021, August 16, 2021, September 17, 2021, September 30, 2021, October 29, 2021,
December 1, 2021, December 3, 2021, January 4, 2022, February 14, 2022, and February 25, 2022; and |
| |
|
|
| |
● |
the description of the
Company’s Common Stock contained in the Company’ Registration Statement on Form 8-A (File No. 001-41277) filed on February
9, 2022, including any amendment or report filed for the purpose of updating such description. |
We hereby undertake to provide
without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy
of any or all documents that are incorporated by reference into this prospectus, but not delivered with the prospectus, other than exhibits
to such documents unless such exhibits are specifically incorporated by reference into this prospectus. These documents are also available
free of charge through the investors section on our website at www.modular-medical.com as soon as practicable after such materials have
been electronically filed with, or furnished to, the SEC. You may request a copy of these filings, at no cost, by writing or telephoning
us at the following:
Modular Medical, Inc.,
16772 W. Bernardo Drive
San Diego, CA 92127
Attention: Corporate Secretary
(858) 800-3500
You should rely only on the
information contained in this prospectus, in any accompanying prospectus supplement, or in any document incorporated by reference herein
or therein. We have not authorized anyone to provide you with any different information. We take no responsibility for, and can provide
no assurance as to the reliability of, any other information that others may provide to you. The information contained in this prospectus,
in any applicable prospectus supplement, and in the documents incorporated by reference herein or therein is accurate only as of the date
such information is presented. Our business, financial condition, results of operations and future prospects may have changed since those
respective dates.
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly
and current reports and other information with the SEC. Our filings with the SEC are available from the SEC’s website at www.sec.gov,
which contains reports, proxy and information statements, and other information regarding issuers that file electronically.
This prospectus supplement
and the accompanying prospectus are part of a registration statement that we filed with the SEC. As permitted by SEC rules, this prospectus
supplement and the accompanying prospectus form a part of the registration statement, but do not contain all of the information that is
included in the registration statement. The registration statement contains more information regarding us and our securities, including
certain exhibits. You can obtain a copy of the registration statement from the SEC’s website.
9,090,910 Shares of Common Stock
PROSPECTUS SUPPLEMENT
Sole Bookrunner
Titan Partners Group
a division of American Capital Partners
February 15, 2024
Modular Medical (NASDAQ:MODD)
Historical Stock Chart
From Apr 2024 to May 2024
Modular Medical (NASDAQ:MODD)
Historical Stock Chart
From May 2023 to May 2024
